What is the ideal number of biopsy cores per lesion in targeted prostate biopsy?

Gokhan Sonmez, Turev Demirtas, Sevket T Tombul, Figen Ozturk, Abdullah Demirtas, Gokhan Sonmez, Turev Demirtas, Sevket T Tombul, Figen Ozturk, Abdullah Demirtas

Abstract

Background: The number of cores to be obtained in targeted biopsy (TB) is important. This study aimed to evaluate the TB outcomes in suspicious prostate lesions classified according to the Prostate Imaging Reporting and Data System (PI-RADS) and to determine the ideal number of biopsy cores per lesion.

Methods: This retrospective study included patients who underwent multiparametric magnetic resonance imaging-guided fusion prostate biopsy owing to increased serum prostate-specific antigen (PSA) levels and suspicious digital rectal examination outcomes in our institute. Patients with PI-RADS <3 lesions, PSA levels >10 ng/ml, and a prior diagnosis of prostate cancer (PCa) (active surveillance) were excluded from the study. The number of biopsy cores to be obtained from each lesion was determined by the clinician.

Results: The study included a total of 418 patients and 684 lesions. Among PI-RADS 3 lesions, clinically significant PCa (sPCa) detection rate was similar in the lesions from which 2 and 3 cores were obtained (9.1% and 10.0%, respectively), whereas it was relatively higher in the lesions from which 4 biopsy cores were obtained (18.5%). Among PI-RADS 4 lesions, sPCa detection rate was similar in the lesions from which 3 and 4 cores were obtained (35.6% and 32.3%, respectively), whereas it was relatively lower in the lesions from which 2 biopsy cores were obtained (17.9%). Among PI-RADS 5 lesions, however, sPCa detection rate was similar in the lesions from which 2, 3, or 4 cores were obtained (47.6%, 46.0%, 48.9%, respectively).

Conclusion: The results indicated that the ideal number of cores to be obtained from each suspicious lesion in TB depends on the characteristics of the lesions. Accordingly, while obtaining 2-3 biopsy cores could be adequate in PI-RADS 4 and 5 lesions, which have a serious risk of cancer, a minimum of 4 biopsy cores should be obtained from PI-RADS 3 lesions to ensure accurate histopathological results.Clinical trial number (ClinicalTrials.gov)NCT03936296.

Keywords: biopsy; core; number; prostate; target.

Conflict of interest statement

All authors declare that there is no conflict of interest in connection with this article.

© 2020 Asian Pacific Prostate Society. Published by Elsevier B.V.

References

    1. Eskra J.N., Rabizadeh D., Pavlovich C.P., Catalona W.J., Luo J. Approaches to urinary detection of prostate cancer. Prostate Cancer Prostatic Dis. 2019;22:362–381.
    1. Ahmed H.U., El-Shater Bosaily A., Brown L.C., Gabe R., Kaplan R., Parmar M.K. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389:815–822.
    1. Fourcade A., Payrard C., Tissot V., Perrouin-Verbe M.A., Demany N., Serey-Effeil S. The combination of targeted and systematic prostate biopsies is the best protocol for the detection of clinically significant prostate cancer. Scand J Urol. 2018;52:174–179.
    1. Rosenkrantz A.B., Verma S., Choyke P., Eberhardt S.C., Eggener S.E., Gaitonde K. Prostate Magnetic 245 Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy 246 in Patients with a Prior Negative Biopsy: A Consensus Statement AUA and SAR. J Urol. 2016;196:1613–1618.
    1. Siddiqui M.M., Rais-Bahrami S., Turkbey B., George A.K., Rothwax J., Shakir N. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. J Am Med Assoc. 2015;313:390–397.
    1. Dimitroulis P., Rabenalt R., Nini A., Hiester A., Esposito I., Schimmöller L. Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy-Are 2 Biopsy Cores per Magnetic Resonance Imaging Lesion Required? J Urol. 2018;200:1030–1034.
    1. Lu A.J., Syed J.S., Ghabili K., Hsiang W.R., Nguyen K.A., Leapman M.S. Role of Core Number and Location in Targeted Magnetic Resonance Imaging-Ultrasound Fusion Prostate Biopsy. Eur Urol. 2019;76:14–17.
    1. Hansen N.L., Barrett T., Lloyd T., Warren A., Samel C., Bratt O. Optimising the number of cores for magnetic resonance imaging-guided targeted and systematic transperineal prostate biopsy. BJU Int. 2019 Jul 15 doi: 10.1111/bju.14865.
    1. Leyh-Bannurah S.R., Kachanov M., Beyersdorff D., Tian Z., Karakiewicz P.I., Tilki D. Minimum Number of MRI Ultrasound Fusion Targeted Biopsy Cores Needed for Prostate Cancer Detection: Multivariable Retrospective Lesion-Based Analyses of Patients Treated with Radical Prostatectomy. J Urol. 2019 doi: 10.1097/JU.0000000000000527. 101097JU0000000000000527.
    1. Arsov C., Rabenalt R., Quentin M., Hiester A., Blondin D., Albers P. Comparison of patient comfort 249 between MR-guided in-bore and MRI/ultrasound fusion-guided prostate 250 biopsies within a prospective randomized trial. World J Urol. 2016;34:215–220.
    1. Nam R.K., Saskin R., Lee Y., Liu Y., Law C., Klotz L.H. Increasing hospital admission rates for 255 urological complications after transrectal ultrasound guided prostate 256 biopsy. J Urol. 2010;183:963–968.
    1. Barentsz J.O., Weinreb J.C., Verma S., Thoeny H.C., Tempany C.M., Shtern F. Synopsis of the PI-RADS v2 guidelines for multiparametric prostate magnetic resonance imaging and recommendations for use. Eur Urol. 2016;69:41–49.
    1. John S., Cooper S., Breau R.H., Flood T.A., Cagiannos I., Lavallee L.T. Multiparametric magnetic resonance imaging - Transrectal ultrasound-guided cognitive fusion biopsy of the prostate: Clinically significant cancer detection rates stratified by the Prostate Imaging and Data Reporting System version 2 assessment category. Can Urol Assoc J. 2018 doi: 10.5489/cuaj.5254. Jun 19.
    1. Sonn G.A., Chang E., Natarajan S., Margolis D.J., Macairan M., Lieu P. Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen. Eur Urol. 2014;65:809–815.
    1. Boesen L., Nørgaard N., Løgager V., Balslev I., Thomsen H.S. A Prospective Comparison of Selective Multiparametric Magnetic Resonance Imaging Fusion-Targeted and Systematic Transrectal Ultrasound-Guided Biopsies for Detecting Prostate Cancer in Men Undergoing Repeated Biopsies. Urol Int. 2017;99:384–391.
    1. Baco E., Rud E., Eri L.M., Moen G., Vlatkovic L., Svindland A. A Randomized Controlled Trial To Assess and Compare the Outcomes of Two-core Prostate Biopsy Guided by Fused Magnetic Resonance and Transrectal Ultrasound Images and Traditional 12-core Systematic Biopsy. Eur Urol. 2016;69:149–156.
    1. Venderink W., van Luijtelaar A., Bomers J.G.R., van der Leest M., Hulsbergen-van de Kaa C., Barentsz J.O. Results of targeted biopsy in men with magnetic resonance imaging lesions classified equivocal, likely or highly likely to be clinically significant prostate cancer. Eur Urol. 2017; Feb 28 pii: S0302-2838(17)30110-0.
    1. Filson C.P., Natarajan S., Margolis D.J., Huang J., Lieu P., Dorey F.J. Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies. Cancer. 2016;122:884–892.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner